Abstract:Abstract Background Based on the current understanding of the role of neuropeptide signalling in migraine, we explored the therapeutic potential of a specific cannabinoid agonist. The aim of the present study was to examine the effect of the synthetic endocannabinoid (eCB) analogue, arachidonyl-2′-chloroethylamide (ACEA), on calcitonin gene-related peptide (CGRP) release in the dura and trigeminal ganglion (TG), as cannabinoids are known to activate G i/o -coupled cannabinoid receptors type 1 (CB1), resulting in neuronal inhibition. Methods The experiments were performed using the hemi-skull model and dissected TGs from male Sprague-Dawley rats. CGRP release was induced by either 60 mM K + (for depolarization-induced stimulation) or 100 nM capsaicin (for transient receptor potential vanilloid 1 (TRPV1) -induced stimulation) and measured using an enzyme-linked immunosorbent assay. The analysis of CGRP release data was combined with immunohistochemistry in order to study the cellular localization of CB1, cannabinoid receptor type 2 (CB2), CGRP and receptor activity modifying protein 1 (RAMP1), a subunit of the functional CGRP receptor, in the TG. Results CB1 was predominantly expressed in neuronal somas in which colocalization with CGRP was observed. Furthermore, CB1 exhibited colocalization with RAMP1 in neuronal Aδ-fibres but was not clearly expressed in the CGRP-immunoreactive C-fibres. CB2 was mainly expressed in satellite glial cells and did not show substantial colocalization with either CGRP or RAMP1. Without stimulation, 140 nM ACEA per se caused a significant increase in CGRP release in the dura but not TG, compared to vehicle. Furthermore, 140 nM ACEA did not significantly modify neither K + - nor capsaicin-induced CGRP release. However, when the TRPV1 blocker AMG9810 (1 mM) was coapplied with ACEA, K + -induced CGRP release was significantly attenuated in the TG and dura. Conclusions Results from the present study indicate that ACEA per se does not exhibit antimigraine potential due to its dual agonistic properties, resulting in activation of both CB1 and TRPV1, and thereby inhibition and stimulation of CGRP release, respectively.

Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat.

High-affinity Partial Agonists of the Vanilloid Receptor.

Endocannabinoid activation of the TRPV1 ion channel is distinct from activation by capsaicin

Rational Design and Validation of a Vanilloid-Sensitive TRPV2 Ion Channel.

Different Vanilloid Agonists Cause Different Patterns of Calcium Response in Cho Cells Heterologously Expressing Rat Trpv1

High Affinity Antagonists of the Vanilloid Receptor.

<i>N</i>-(3-Acyloxy-2-benzylpropyl)-<i>N</i>‘-[4-(methylsulfonylamino)benzyl]thiourea Analogues: Novel Potent and High Affinity Antagonists and Partial Antagonists of the Vanilloid Receptor

Attenuation of thermal nociception and hyperalgesia by VR1 blockers

Non-vanillyl Resiniferatoxin Analogues As Potent and Metabolically Stable Transient Receptor Potential Vanilloid 1 Agonists

The role of adenosine receptor ligands on inflammatory pain: possible modulation of TRPV1 receptor function

N-[4-(Methylsulfonylamino)benzyl]thiourea Analogues As Vanilloid Receptor Antagonists: Analysis of Structure–activity Relationships for the ‘C-Region’

The role of dopamine receptors in ventrolateral orbital cortex-evoked antinociception in a rat formalin test model.

The antinociceptive potency of N-arachidonoyl-dopamine (NADA) and its interaction with endomorphin-1 at the spinal level

Modulation of muscle rNaV1.4 Na+ channel isoform by arachidonic acid and its non-metabolized analog.

N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating both Cannabinoid and Vanilloid Receptors

Anandamide modulates carotid sinus nerve afferent activity via TRPV1 receptors increasing responses to heat

AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties

Dual action of the cannabinoid receptor 1 ligand arachidonyl-2′-chloroethylamide on calcitonin gene-related peptide release

[Effect of Intrathecal Injection of Dopamine Receptor Agonists/antagonists on Pain and Acupuncture Analgesia in Rats].

The Role of Dopamine Receptors in Ventrolateral Orbital Cortex-Evoked Anti-Nociception in A Rat Model of Neuropathic Pain

Biochemistry and pharmacology of endovanilloids